| Статус: | Enrolling by invitation |
| Фаза: | Phase 1 |
| Начало: | 1 октября 2024 г. |
| Окончание: | 1 февраля 2025 г. |
| Описание: | The study should evaluate the biological distribution of [177Lu]Lu-BQ7876 in patients with prostate cancer. The objective are: 1. To evaluate the content of [177Lu]Lu-BQ7876 in the blood of patients with prostate cancer at different time points after a single intravenous administration. 2. To assess the distribution of [177Lu]Lu-BQ7876 in normal tissues and tumors at different time points. 3. To evaluate dosimetry of [177Lu]Lu-BQ7876. 4. To study the safety and tolerability of the drug [177Lu]Lu-BQ7876 after a single injection. |
| смотреть на ClinicalTrials.gov |
| Статус: | Enrolling by invitation |
| Фаза: | Phase 1 |
| Начало: | 14 апреля 2024 г. |
| Окончание: | 31 декабря 2024 г. |
| Описание: | The study should evaluate the biological distribution of [123I]I-DARPIN-Ec1 in patients with lung and ovarian cancer The primary objective are: 1. To assess the distribution of [123I]I-DARPIN-Ec1 in normal tissues and tumors at different time intervals. 2. To evaluate dosimetry of [123I]I-DARPIN-Ec1. 3. To study the safety and tolerability of the drug [123I]I-DARPIN-Ec1 after a single injection in a diagnostic dosage. The secondary objective are: 1. To compare the obtained [123I]I-DARPIN-Ec1 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in lung and ovarian cancer patients. |
| смотреть на ClinicalTrials.gov |
| Статус: | Enrolling by invitation |
| Фаза: | Phase 1 |
| Начало: | 19 октября 2023 г. |
| Окончание: | 30 декабря 2024 г. |
| Описание: | The study should evaluate the biological distribution of [99mTc]Tc-BQ0413 in patients with prostate cancer. The primary objective are: 1. To assess the distribution of [99mTc]Tc- BQ0413 in normal tissues and tumors at different time intervals. 2. To evaluate dosimetry of [99mTc]Tc- BQ0413. 3. To study the safety and tolerability of the drug [99mTc]Tc- BQ0413 after a single injection in a diagnostic dosage. The secondary objective are: 1. To compare the obtained [99mTc]Tc- BQ0413 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in prostate cancer patients. |
| смотреть на ClinicalTrials.gov |
| Статус: | Recruiting |
| Фаза: | Phase 1 |
| Начало: | 1 сентября 2023 г. |
| Окончание: | 1 сентября 2024 г. |
| Описание: | The study should evaluate distribution of [123I] I-(HE)3-G3 in patients with primary HER2-positive and HER2-negative breast cancer |
| смотреть на ClinicalTrials.gov |
| Статус: | Active, not recruiting |
| Фаза: | Phase 1 |
| Начало: | 3 июля 2023 г. |
| Окончание: | 31 декабря 2024 г. |
| Описание: | The study should evaluate the biological distribution of 99mTc-DB8 in patients with prostate cancer and breast cancer. The primary objective are: 1. To assess the distribution of [99mTc]Tc- DB8 in normal tissues and tumors at different time intervals. 2. To evaluate dosimetry of [99mTc]Tc- DB8. 3. To study the safety and tolerability of the drug [99mTc]Tc- DB8 after a single injection in a diagnostic dosage. The secondary objective are: 1. To compare the obtained [99mTc]Tc- DB8 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in prostate cancer and breast cancer patients. |
| смотреть на ClinicalTrials.gov |
| Статус: | Active, not recruiting |
| Фаза: | Phase 1 |
| Начало: | 3 июля 2023 г. |
| Окончание: | 31 декабря 2024 г. |
| Описание: | The study should evaluate the biological distribution of 99mTc-DB8 in patients with prostate cancer and breast cancer. The primary objective are: 1. To assess the distribution of [99mTc]Tc- DB8 in normal tissues and tumors at different time intervals. 2. To evaluate dosimetry of [99mTc]Tc- DB8. 3. To study the safety and tolerability of the drug [99mTc]Tc- DB8 after a single injection in a diagnostic dosage. The secondary objective are: 1. To compare the obtained [99mTc]Tc- DB8 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in prostate cancer and breast cancer patients. |
| смотреть на ClinicalTrials.gov |
| Статус: | Completed |
| Фаза: | не указано |
| Начало: | 20 декабря 2022 г. |
| Окончание: | 1 декабря 2023 г. |
| Описание: | An open-label, single center study with 99mTc-DARPinG3 SPECT/CT and biopsies of primary tumour and metastatic lymph nodes in breast cancer patients, where the primary endpoint of the study is to find out the correlation between the HER2 expression measured by 99mTc-DARPinG3 SPECT/CT and standard histopathology from relevant tumor and lymph node biopsies. |
| смотреть на ClinicalTrials.gov |
| Статус: | Enrolling by invitation |
| Фаза: | Phase 1 |
| Начало: | 1 октября 2022 г. |
| Окончание: | 31 декабря 2024 г. |
| Описание: | The study should evaluate the biological distribution of [99mTc]Tc(CO)3-(HE)3-Ec1 in patients with solid tumor The primary objective are: 1. To assess the distribution of [99mTc]Tc(CO)3-(HE)3-Ec1 in normal tissues and tumors at different time intervals. 2. To evaluate dosimetry of [99mTc]Tc(CO)3-(HE)3-Ec1 . 3. To study the safety and tolerability of the drug [99mTc]Tc(CO)3-(HE)3-Ec1 after a single injection in a diagnostic dosage. The secondary objective are: 1. To compare the obtained [99mTc]Tc(CO)3-(HE)3-Ec1 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in solid tumor patients. |
| смотреть на ClinicalTrials.gov |
| Статус: | Completed |
| Фаза: | Phase 2 |
| Начало: | 1 мая 2022 г. |
| Окончание: | 31 декабря 2022 г. |
| Описание: | An open-label, single center study with 99mTc-ADAPT6 SPECT and biopsies of primary tumour and metastatic lymph nodes in breast cancer patients, where the primary endpoint of the study is to find out the correlation between the HER2 expression measured by 99mTc-ADAPT6 SPECT and standard histopathology from relevant tumor and lymph node biopsies. |
| смотреть на ClinicalTrials.gov |
| Статус: | Completed |
| Фаза: | Phase 1 |
| Начало: | 22 декабря 2021 г. |
| Окончание: | 1 марта 2023 г. |
| Описание: | The study should evaluate distribution of 99mTc-ZHER2:41071 Affibody molecule in patients with primary HER2-positive and HER2-negative breast cancer The primary objectives are: 1. To assess distribution of 99mTc-ZHER2:41071 in normal tissues and in tumors over time; 2. To evaluate dosimetry of 99mTc-ZHER2:41071; 3. To obtain initial information concerning safety and tolerability of 99mTc-ZHER2:41071 after single intravenous injection: The secondary objectives are: 1. To compare the tumor imaging data with the data concerning HER2 expression obtained by immunohistochemistry (IHC) and/or fluorescent in situ hybridization (FISH) analysis of biopsy samples. |
| смотреть на ClinicalTrials.gov |